We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Bio-Techne

Bio-Techne Corporation is a developer and manufacturer of high-quality purified proteins and reagent solutions - nota... read more Featured Products: More products

Download Mobile App




Benchtop Automated ELISA Platform Achieves Consistent Biomarker Detection

By LabMedica International staff writers
Posted on 06 Apr 2023
Print article
Image: More than 1,000 Ella instruments are now in operation (Photo courtesy of Bio-Techne)
Image: More than 1,000 Ella instruments are now in operation (Photo courtesy of Bio-Techne)

There is growing demand across the scientific and clinical research fields for an immunoassay solution that is both fast and efficient, while ensuring precise and reliable analysis of biomarkers. Furthermore, researchers aim for a higher analysis speed, producing fully analyzed data in less time without sacrificing long-term consistency. Automation offers an opportunity to enhance the efficiency of critical quality steps throughout the discovery to commercialization continuum, while reducing sources of variability and operator bias to provide more accurate and reliable results.

The Ella automated immunoassay instrument from Bio-Techne Corporation (Minneapolis, MN, USA) streamlines the laborious manual process associated with traditional immunoassays, delivering quicker results, increased lab efficiency and reduced human error. The automation of key steps in the assay workflow ensures high levels of reproducibility and data quality, which are crucial factors in research and translational applications.

Manufactured under Bio-Techne's ProteinSimple brand, Ella represents a significant advancement in immunoassays. In less than 90 minutes, it delivers highly reproducible assay data with consistent biomarker detection, and without the need for any manual steps. The assay performance behind that data includes sub-picogram level sensitivity, 4+ logs of dynamic range, and precision which equals the best laboratory automation. With an expanding assay menu of over 250 analytes, Ella supports therapeutic areas across neuroscience, cell and gene therapy, immunology, and cancer. Bio-Techne has achieved a significant milestone, with over 1,000 Ella automated immunoassay instruments now in use.

"We are proud of Ella's contributions towards our mission to catalyze advances in science and medicine." said Will Geist, President of Bio-Techne's Protein Sciences Segment. "We look forward to celebrating new milestones in the future with Ella as the underlying need for greater analytical speed, precision, and reproducibility remains a core driver across clinical and research sectors."

Related Links:
Bio-Techne Corporation

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.